NewGenIvf grants 73,647 options to director

NewGenIvf Group Ltd director Siu Wing Fung Alfred received a grant of 73,647 Employee Share Options as part of his compensation.

Rhea-AI Filing Summary

NewGenIvf Group Ltd director Siu Wing Fung Alfred received a grant of 73,647 Employee Share Options as part of his compensation. These options have an exercise price of $0.0001 per Class B ordinary share and expire on July 8, 2033.

The options were granted under the company’s 2024 Share Incentive Plan and an option agreement dated July 8, 2026. They vest over 36 months, with 10% vesting on August 8, 2026 and the remainder vesting in approximately 2.6% monthly tranches, aligning incentives over a multi-year period.

Insider Trade Summary

Grant/Award: 73,647 shares

Grant/Award 1 txn

Insider Siu Wing Fung Alfred

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Share Options	73,647	$0.00	$0.00

Holdings After Transaction: Employee Share Options — 73,647 contracts (Direct)

Footnotes (2)

1. F1. The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement, dated July 8, 2026, between the Issuer and the Reporting Person (the "Option Agreement").
2. F2. The Employee Share Options vest monthly, over 36 months, with the first tranche of 10% vesting on August 8, 2026. Thereafter, the Employee Share Options vest monthly in tranches of approximately 2.6%.

Key Figures

Options granted: 73,647 options Exercise price: $0.0001 per share Underlying shares: 73,647 Class B shares +5 more

8 metrics

Options granted 73,647 options Employee Share Options granted to director on July 8, 2026

Exercise price $0.0001 per share Exercise price for each underlying Class B ordinary share

Underlying shares 73,647 Class B shares Underlying security for the Employee Share Options

Post-grant derivative holdings 73,647 options Total Employee Share Options following the transaction

Vesting period 36 months Options vest monthly over three years

Initial vesting tranche 10% First portion vests on August 8, 2026

Subsequent vesting rate ≈2.6% monthly Remaining options vest each month after initial tranche

Option expiration July 8, 2033 Expiration date of Employee Share Options

Key Terms

Employee Share Options, 2024 Share Incentive Plan, vesting, Class B ordinary shares

4 terms

Employee Share Options financial

"The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan"

2024 Share Incentive Plan financial

"granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement"

vesting financial

"The Employee Share Options vest monthly, over 36 months, with the first tranche of 10% vesting on August 8, 2026."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Class B ordinary shares financial

"underlying_security_title: "Class B ordinary shares""

Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NewGenIvf (NIVF) director Siu Wing Fung Alfred report on this Form 4?

He reported a grant of 73,647 Employee Share Options as compensation. The options relate to Class B ordinary shares and were awarded under NewGenIvf’s 2024 Share Incentive Plan, rather than being bought in the open market.

How many options did the NewGenIvf (NIVF) director receive and at what exercise price?

He received 73,647 Employee Share Options with an exercise price of $0.0001 per underlying Class B ordinary share. This low exercise price effectively makes the award similar to equity compensation that can be exercised at a nominal cost if vested.

When do the NewGenIvf (NIVF) options granted to the director start vesting and over what period?

The options start vesting on August 8, 2026, when 10% of the grant vests. The remaining options then vest monthly over a total 36‑month period in tranches of approximately 2.6%, spreading vesting across three years.

What is the expiration date of the Employee Share Options granted by NewGenIvf (NIVF)?

The Employee Share Options expire on July 8, 2033. This long-dated expiration gives the director several years after vesting to decide when to exercise, aligning the award with longer-term company performance.

Are the NewGenIvf (NIVF) Form 4 transactions open-market buys or compensation awards?

They are compensation awards, not open-market purchases. The filing describes an “A” code transaction, meaning a grant or award of 73,647 Employee Share Options under the 2024 Share Incentive Plan and an option agreement with the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2026 - 03:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siu Wing Fung Alfred

(Last) (First) (Middle)

C/O 1/F, PIER 2, CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

HONG KONG

(Country)

2. Issuer Name and Ticker or Trading Symbol
NewGenIvf Group Ltd [ NIVF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Share Options	$0.0001	07/08/2026		A		73,647(1)		08/08/2026(2)	07/08/2033	Class B ordinary shares	73,647	$0(1)	73,647	D

Explanation of Responses:

1. The Employee Share Options were granted pursuant to the Issuer's 2024 Share Incentive Plan and an employee share option agreement, dated July 8, 2026, between the Issuer and the Reporting Person (the "Option Agreement").

2. The Employee Share Options vest monthly, over 36 months, with the first tranche of 10% vesting on August 8, 2026. Thereafter, the Employee Share Options vest monthly in tranches of approximately 2.6%.

	/s/ Siu Wing Fung Alfred	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)